COHU Surged 24% as Test-Cell Utilization Crossed 80%

Cohu jumped 24.14% to $57.08 over five sessions after test-cell utilization crossed the critical 80% mark. That single operational metric serves as the unofficial line between a semiconductor equipment supplier bleeding cash in a back-end cyclical trough and one suddenly blessed with operating leverage. Five days ago, Cohu traded at $45.98. Today, the stock sits at the upper edge of a textbook post-earnings announcement drift, having retained a +12.5% advance seven days after its earnings gap, propelled by an $850 million artificial intelligence test pipeline.

The market loves an inflection story, particularly one with "AI server thermal testing" attached to the press release. But beneath the celebratory chart lies a familiar semiconductor puzzle: whether a company whose top 10 customers command up to 60% of sales is executing a secular breakout or simply enjoying the violent upswing of a volatile cycle.

The 80% Inflection and an $850 Million Pipeline

Cohu makes test handlers, contactors, and automated test inspection equipment. When chipmakers stop expanding factory floors, companies like Cohu absorb the hit first. Conversely, when factory utilization ticks up, earnings explode higher because fixed costs are already paid for. Management is capitalizing on that operating leverage, guiding fiscal 2026 revenue to accelerate roughly 35% year-over-year into a range of $610 million to $615 million, with forward earnings per share projected at $1.85.

What cushions the bottom of this business is its razor-and-blade mechanics. Consumables and test contactors account for 50% to 55% of total revenue. That recurring revenue stream allowed Cohu to generate $34.9 million in positive free cash flow over the trailing twelve months despite enduring one of the most punishing chip inventory corrections in recent memory.

The balance sheet offers structural ballast: $219.6 million in cash and equivalents, a current ratio of 5.74x, and a 1.5% convertible note maturing in 2031 with no maintenance covenants. Liquidity is not the debate here. The debate is whether the market is paying $57.08 for durable AI test infrastructure or rental upside in an assembly-and-test cycle that will peak as abruptly as it rebounded.

The $59.32 Resistance Wall Meets 98% Realized Volatility

The TradeFlare Technical Analysis team registered a bullish verdict with a 72 conviction score, pointing to a clean breakout from $45.66 support that carried the price back over both its 20-day and 50-day moving averages. The modeled trade setup specifies an entry at $57.08, a stop-loss at $52.44 (limiting downside to -8.13%), and a take-profit target at $68.70 (+20.36%), framing an asymmetric 1:2.50 risk-to-reward ratio.

There is, however, immediate friction directly overhead. Intermediate supply looms at $59.32—just 3.9% above current trading. Breaking through that shelf requires continuous institutional volume, yet recent five-day volume came in at a modest 0.66x relative volume ratio.

This is where internal models clash. While the Technical team sees smooth sailing toward $68.70 once $59.32 is breached, the Risk Assessment team slapped the ticker with a HIGH risk rating and an 85 conviction score. That is not a marginal difference in perspective; it is an outright dispute over survivability during pullbacks. The Risk team highlights Cohu’s 60-day annualized realized volatility running at 98%, paired with an average true range of 5.55%. That implies normal day-to-day noise can wipe out an 8% stop-loss in a single morning session before the broader trend even has an opportunity to resolve. You are being asked to trade an asset that exhibits biotech-grade turbulence inside a hardware valuation envelope.

The OSAT Concentration Gamble Against the Street's $71 Targets

Wall Street coverage has turned decidedly one-sided. Institutional ownership stands at 94.7%, with approximately 80% of covering analysts holding Buy ratings and consensus price targets clustered tightly between $69 and $71. The narrative battle is spilling into headlines across the sector. Zacks reported: "Teradyne Rides on Strong UltraFLEXplus Demand: Can It Beat KLAC & COHU?" while framing the race to capture advanced packaging test spend.

Yet institutional unanimity introduces its own vulnerability. Cohu relies on outsourced semiconductor assembly and test providers (OSATs) and automotive/industrial chipmakers for the majority of its shipments. When automotive demand softens, OSATs halt capital expenditure overnight. With Cohu's top 10 accounts representing up to 60% of total revenue, any delay in test-cell capex by a single tier-one packaging house could dismantle the guided 35% top-line acceleration for FY26.

Investors tracking the move on the Full COHU analysis on TradeFlare can see the fundamental tension laid bare: the Sentiment team scores analyst posture at a sky-high +68 on the back of rising price targets, while realized volatility screams that the market has not priced in the downside of a cyclical pause. Reclaiming $57.08 after a 24.14% surge looks impressive on a daily chart. But until Cohu absorbs the overhead supply sitting at $59.32, buyers are paying full price for an earnings recovery that still needs several quarters to materialize.

This article is AI-generated research and educational content only. Not financial advice.